Mankind Pharma is paying €48m to acquire a 70% stake in Armed Cell, the Paul Stoffels-chaired CAR-T start-up that a day earlier bought Lakefront’s preclinical pipeline, giving the Indian major its first global innovation toehold.
Mankind Pharma is paying €48m to acquire a 70% stake in Armed Cell, the Paul Stoffels-chaired CAR-T start-up that a day earlier bought Lakefront’s preclinical pipeline, giving the Indian major its first global innovation toehold.